Who owns QIAGEN N.V. (QGEN)? Elite investor 13F holders
2 tracked elite investors reported holding QIAGEN N.V as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | Qiagen Nv - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2904778.00 USD | 74291.000000 | Shares | add | Original filing |
| Tudor Investment | Qiagen Nv - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1649551.00 USD | 42188.000000 | Shares | add | Original filing |
| Ancora Advisors / Ancora Holdings | Qiagen Nv - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.